FirstWord

The Neuralink competitor has raised $430 million in total as it works to commercialise its wireless brain-computer interface (BCI) system.

The deal follows a $787-million financing for Earendil, backed by Sanofi and Pfizer.

Amgen, Lilly and Merck & Co. are among the investors backing the biotech's agentic data platform for rapid protein design.

Several panellists expressed "serious concerns" about whether Galleri has demonstrated a clinical benefit.

UltraSight wants AI-guided scanning to become part of daily workflows across multiple care settings rather than remain a single-unit pilot, CEO Davidi Vortman told FirstWord.

Beyond treatment intent, the complete clinical workflow will include tools for the physician, physicist, dosimetrist, therapist and nurse. It builds on collaboration with the University of Michigan an...

Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregio...

DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...

Oral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patientsNew external control arm analysis of avutometinib plus defactinib versu...

Hyperion will offer digital demos of the company’s IVY™ solution, designed to address the high variability and failure rate in difficult-to-access IV placementsWe look forward to demonstrating how IVY...